Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod

Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod

Fingolimod represents a highly effective disease-modifying drug in patients with active relapsing-remitting multiple sclerosis (RRMS). Its immunosuppressive effects can mediate adverse events like increased risk of cancer development or appearance of opportunistic infections. Progressive multifocal...

Full description

Bibliographic Details
Main Authors:	Fabian Maass, Philipp von Gottberg, Jonas Franz, Christine Stadelmann, Mathias Bähr, Martin S. Weber
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-02-01
Series:	Frontiers in Neurology
Subjects:	multiple sclerosis fingolimod (FTY720) lung cancer RRMS (relapsing-Remitting MS) PML–progressive multifocal leucoencephalopathy
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2021.561158/full

Similar Items

Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis
by: Heather Gwen Mack, et al.
Published: (2016-12-01)

Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
by: Joseph R. Berger, et al.
Published: (2023-03-01)

Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner
by: Abhisarika Patnaik, et al.
Published: (2020-04-01)

Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease
by: Pablo Bascuñana, et al.
Published: (2023-02-01)

Fingolimod does not prevent syndecan-4 shedding from the endothelial glycocalyx in a cultured human umbilical vein endothelial cell model of vascular injury
by: Elissa M. Milford, et al.
Published: (2022-08-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod
by: Henryk Jęśko, et al.
Published: (2021-07-01)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
by: Tony Sehr, et al.
Published: (2020-05-01)

Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells
by: Ahmet Eken, et al.
Published: (2019-02-01)

A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis
by: Claudia Fracasso, et al.
Published: (2022-06-01)

Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01)

Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report
by: Nicolas Lambert, et al.
Published: (2022-05-01)

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
by: Thomas Roux, et al.
Published: (2017-05-01)

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
by: Nikolaos Petsas, et al.
Published: (2019-03-01)

Effect of immunomodulator, fingolimod, on ischemia reperfusion testicular injury in rats: Targeting the role of sphingolipid rheostat (fingolimod on I/R induced testicular injury)
by: Marwa N. Emam, et al.
Published: (2017-06-01)

Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis
by: Kathrin Bail, et al.
Published: (2017-07-01)

Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod
by: Raquel Piñar Morales, et al.
Published: (2022-02-01)

Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review
by: Tulika Chatterjee, et al.
Published: (2022-01-01)

Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report
by: D. Mickeviciene, et al.
Published: (2022-08-01)

Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model
by: Naseer Ahmed, et al.
Published: (2020-09-01)

Magnetic resonance imaging may simulate progressive multifocal leucoencephalopathy in a patient with chronic lymphocytic leukemia after fludarabine therapy
by: Kalita J, et al.
Published: (2008-01-01)

Protein phosphatase 2A regulates xanthine oxidase-derived ROS production in macrophages and influx of inflammatory monocytes in a murine gout model
by: Sandy Elsayed, et al.
Published: (2022-11-01)

IMMUNOLOGICAL PRECONDITIONS OF CONVERSION FROM NATALIZUMAB TO FINGOLIMOD
by: E. V. Popova, et al.
Published: (2017-12-01)

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder
by: Wei Lin, et al.
Published: (2023-04-01)

A case of progressive multifocal leukoencephalopathy in a HIV-infected female patient
by: E A Samotolkina, et al.
Published: (2016-11-01)

Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy – a realistic possibility?
by: Ivan Jelcic, et al.
Published: (2017-10-01)

Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report
by: Troppmann Martina, et al.
Published: (2012-07-01)

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
by: Andrea C. Diaz Diaz, et al.
Published: (2022-07-01)

Anti-Inflammatory Treatment with FTY720 Starting after Onset of Symptoms Reverses Synaptic Deficits in an AD Mouse Model
by: Georgia-Ioanna Kartalou, et al.
Published: (2020-11-01)

Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters
by: Anne Gomez-Brouchet, et al.
Published: (2022-01-01)

Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis
by: Luis Del Valle, et al.
Published: (2019-08-01)

Is There a (Host) Genetic Predisposition to Progressive Multifocal Leukoencephalopathy?
by: Eli eHatchwell
Published: (2015-05-01)

Are different degrees of lymphopenia for FTY720 associated with serious infectious-type events? No
by: Catalina Márquez-Martín, et al.
Published: (2022-07-01)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
by: Tjalf Ziemssen, et al.
Published: (2021-03-01)

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod
by: Yasuyuki Kihara, et al.
Published: (2022-06-01)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
by: Marina Boziki, et al.
Published: (2021-08-01)

Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
by: Chloé Medrano, et al.
Published: (2019-11-01)

Identification of Key Ferroptosis-Related Genes in the Peripheral Blood of Patients with Relapsing-Remitting Multiple Sclerosis and Its Diagnostic Value
by: Xi Song, et al.
Published: (2023-03-01)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
by: Anna Jamroz-Wiśniewska, et al.
Published: (2021-04-01)

Not All Strokes Are Strokes - An Example of Diagnostic Confirmation Bias
by: Melanie Dani, et al.
Published: (2019-01-01)